NEUROPACE, INC. (NPCE) Spending and interest coverage
- R&D / revenue · 12 months: Value 25.88%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 9.17%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 25.88% | Research and development expense / revenue. Period ending 2026-06-30. $27.69M ÷ $106.99M × 100 ≈ 25.88% |
| Stock-based compensation / revenue · 12 months | 9.17% | Share-based compensation / revenue. Period ending 2026-06-30. $9.82M ÷ $106.99M × 100 ≈ 9.17% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 27.69M USD | Research and Development Expense |
| Revenue | 106.99M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.82M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -12.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.69M | $106.99M | $9.82M | $-12.14M | (m) | 25.88% | 9.17% | (m) | (m) |
| 2026-03-31 | $27.64M | $99.53M | $10.74M | $-16.76M | (m) | 27.77% | 10.79% | (m) | (m) |
| 2025-12-31 | $27.89M | $99.99M | $11.09M | $-16.34M | (m) | 27.89% | 11.09% | (m) | (m) |
| 2025-09-30 | $26.91M | $94.86M | $11.09M | $-18.22M | (m) | 28.37% | 11.69% | (m) | (m) |
| 2025-06-30 | $26.09M | $88.57M | $11.05M | $-19.87M | (m) | 29.46% | 12.47% | (m) | (m) |
| 2025-03-31 | $25.31M | $84.31M | $10.37M | $-19.27M | (m) | 30.02% | 12.30% | (m) | (m) |
| 2024-12-31 | $23.65M | $79.91M | $10.28M | $-21.67M | (m) | 29.60% | 12.87% | (m) | (m) |
| 2024-09-30 | $22.98M | $76.45M | $10.04M | $-23.07M | (m) | 30.06% | 13.13% | (m) | (m) |
| 2024-06-30 | $22.02M | $71.82M | $9.87M | $-24.78M | (m) | 30.66% | 13.74% | (m) | (m) |
| 2024-03-31 | $21.30M | $69.07M | $9.97M | $-26.40M | $8.81M | 30.84% | 14.44% | -3.00× | Reported |
| 2023-12-31 | $20.78M | $65.42M | $9.56M | $-27.17M | $8.52M | 31.76% | 14.61% | -3.19× | Reported |
| 2023-09-30 | $20.49M | $60.20M | $9.28M | $-31.98M | $8.22M | 34.04% | 15.41% | -3.89× | Reported |
| 2023-06-30 | $21.31M | $54.93M | $9.04M | $-36.23M | $7.94M | 38.79% | 16.45% | -4.56× | Reported |
| 2023-03-31 | $21.63M | $48.62M | $8.99M | $-39.35M | $7.66M | 44.49% | 18.48% | -5.13× | Reported |
| 2022-12-31 | $21.95M | $45.52M | $8.35M | $-40.79M | $7.53M | 48.21% | 18.34% | -5.42× | Reported |
| 2022-09-30 | $22.20M | $43.73M | $8.15M | $-39.95M | $7.45M | 50.77% | 18.64% | -5.36× | Reported |
| 2022-06-30 | $20.92M | $42.91M | $7.07M | $-35.99M | $7.37M | 48.75% | 16.49% | -4.88× | Reported |
| 2022-03-31 | $19.69M | $45.34M | $5.57M | $-29.63M | $7.39M | 43.42% | 12.29% | -4.01× | Reported |
| 2021-12-31 | $18.21M | $45.18M | $4.29M | $-23.74M | $7.41M | 40.30% | 9.49% | -3.20× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $15.70M | $41.14M | $1.38M | $-13.05M | $11.49M | 38.15% | 3.35% | -1.14× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |